| Dr Michael Chustek, MD | |
|
500 N Bridge St, Bridgewater, NJ 08807-2135 | |
| (908) 725-2800 | |
| Not Available |
| Full Name | Dr Michael Chustek |
|---|---|
| Gender | Male |
| Speciality | Psychiatry |
| Experience | 20 Years |
| Location | 500 N Bridge St, Bridgewater, New Jersey |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1609083393 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084P0800X | Psychiatry & Neurology - Psychiatry | 25MA08416500 (New Jersey) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Nynj Psychiatric Associates Llc | 2961689989 | 27 |
News Archive
Erlotinib as first-line therapy in patients with advanced non-small-cell lung cancer is equivalent to chemotherapy with regard to overall survival, an "all-comers" phase II trial has shown.
Clinicians use the do-not-resuscitate (DNR) order not only as a guide for therapeutic decisions during a cardiopulmonary arrest but also as a surrogate for broader treatment directives, according to a study by Amy Sanderson M.D., of Boston Children's Hospital, M.A., and colleagues.
Cancer is a notoriously difficult disease to treat. Not only do a wide variety of cancers exist, requiring specialized treatments for each type, but cancer cells within an individual can morph and render previously potent therapeutics ineffective.
Mothers of children with autism see their careers disproportionally affected as they confront greater demands on their time, inflexible workplaces and increased medical costs, according to a new study by researchers at Washington State University Vancouver.
NCCN recently received a research grant from Allos Therapeutics, Inc. to evaluate the role of pralatrexate in the treatment of select hematologic malignancies and solid tumors. Pralatrexate is the only agent currently approved by the FDA to treat patients with relapsed or refractory peripheral T-cell lymphoma. Investigators from NCCN Member Institutions are eligible to apply for the research funding.
› Verified 6 days ago
| Entity Name | Barnabas Health Medical Group, Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1447206420 PECOS PAC ID: 0648172809 Enrollment ID: O20040127000361 |
News Archive
Erlotinib as first-line therapy in patients with advanced non-small-cell lung cancer is equivalent to chemotherapy with regard to overall survival, an "all-comers" phase II trial has shown.
Clinicians use the do-not-resuscitate (DNR) order not only as a guide for therapeutic decisions during a cardiopulmonary arrest but also as a surrogate for broader treatment directives, according to a study by Amy Sanderson M.D., of Boston Children's Hospital, M.A., and colleagues.
Cancer is a notoriously difficult disease to treat. Not only do a wide variety of cancers exist, requiring specialized treatments for each type, but cancer cells within an individual can morph and render previously potent therapeutics ineffective.
Mothers of children with autism see their careers disproportionally affected as they confront greater demands on their time, inflexible workplaces and increased medical costs, according to a new study by researchers at Washington State University Vancouver.
NCCN recently received a research grant from Allos Therapeutics, Inc. to evaluate the role of pralatrexate in the treatment of select hematologic malignancies and solid tumors. Pralatrexate is the only agent currently approved by the FDA to treat patients with relapsed or refractory peripheral T-cell lymphoma. Investigators from NCCN Member Institutions are eligible to apply for the research funding.
› Verified 6 days ago
| Entity Name | Nynj Psychiatric Associates Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477859544 PECOS PAC ID: 2961689989 Enrollment ID: O20110531000452 |
News Archive
Erlotinib as first-line therapy in patients with advanced non-small-cell lung cancer is equivalent to chemotherapy with regard to overall survival, an "all-comers" phase II trial has shown.
Clinicians use the do-not-resuscitate (DNR) order not only as a guide for therapeutic decisions during a cardiopulmonary arrest but also as a surrogate for broader treatment directives, according to a study by Amy Sanderson M.D., of Boston Children's Hospital, M.A., and colleagues.
Cancer is a notoriously difficult disease to treat. Not only do a wide variety of cancers exist, requiring specialized treatments for each type, but cancer cells within an individual can morph and render previously potent therapeutics ineffective.
Mothers of children with autism see their careers disproportionally affected as they confront greater demands on their time, inflexible workplaces and increased medical costs, according to a new study by researchers at Washington State University Vancouver.
NCCN recently received a research grant from Allos Therapeutics, Inc. to evaluate the role of pralatrexate in the treatment of select hematologic malignancies and solid tumors. Pralatrexate is the only agent currently approved by the FDA to treat patients with relapsed or refractory peripheral T-cell lymphoma. Investigators from NCCN Member Institutions are eligible to apply for the research funding.
› Verified 6 days ago
| Entity Name | Medop Behavioral Health Associates Of New Jersey Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1982995569 PECOS PAC ID: 2163691353 Enrollment ID: O20110804000021 |
News Archive
Erlotinib as first-line therapy in patients with advanced non-small-cell lung cancer is equivalent to chemotherapy with regard to overall survival, an "all-comers" phase II trial has shown.
Clinicians use the do-not-resuscitate (DNR) order not only as a guide for therapeutic decisions during a cardiopulmonary arrest but also as a surrogate for broader treatment directives, according to a study by Amy Sanderson M.D., of Boston Children's Hospital, M.A., and colleagues.
Cancer is a notoriously difficult disease to treat. Not only do a wide variety of cancers exist, requiring specialized treatments for each type, but cancer cells within an individual can morph and render previously potent therapeutics ineffective.
Mothers of children with autism see their careers disproportionally affected as they confront greater demands on their time, inflexible workplaces and increased medical costs, according to a new study by researchers at Washington State University Vancouver.
NCCN recently received a research grant from Allos Therapeutics, Inc. to evaluate the role of pralatrexate in the treatment of select hematologic malignancies and solid tumors. Pralatrexate is the only agent currently approved by the FDA to treat patients with relapsed or refractory peripheral T-cell lymphoma. Investigators from NCCN Member Institutions are eligible to apply for the research funding.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Michael Chustek, MD 500 N Bridge St, Bridgewater, NJ 08807-2135 Ph: () - | Dr Michael Chustek, MD 500 N Bridge St, Bridgewater, NJ 08807-2135 Ph: (908) 725-2800 |
News Archive
Erlotinib as first-line therapy in patients with advanced non-small-cell lung cancer is equivalent to chemotherapy with regard to overall survival, an "all-comers" phase II trial has shown.
Clinicians use the do-not-resuscitate (DNR) order not only as a guide for therapeutic decisions during a cardiopulmonary arrest but also as a surrogate for broader treatment directives, according to a study by Amy Sanderson M.D., of Boston Children's Hospital, M.A., and colleagues.
Cancer is a notoriously difficult disease to treat. Not only do a wide variety of cancers exist, requiring specialized treatments for each type, but cancer cells within an individual can morph and render previously potent therapeutics ineffective.
Mothers of children with autism see their careers disproportionally affected as they confront greater demands on their time, inflexible workplaces and increased medical costs, according to a new study by researchers at Washington State University Vancouver.
NCCN recently received a research grant from Allos Therapeutics, Inc. to evaluate the role of pralatrexate in the treatment of select hematologic malignancies and solid tumors. Pralatrexate is the only agent currently approved by the FDA to treat patients with relapsed or refractory peripheral T-cell lymphoma. Investigators from NCCN Member Institutions are eligible to apply for the research funding.
› Verified 6 days ago
Dr. Laura Owens Bakey, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 500 N Bridge St, Bridgewater, NJ 08807 Phone: 908-725-2800 Fax: 908-704-1790 | |
Dr. Justin Joseph Lo Re, D.O. Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 1125 Route 22 Ste 155, Bridgewater, NJ 08807 Phone: 732-667-1123 Fax: 732-560-3206 | |
Dr. Marcella S Bernson, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 500 N Bridge St, Bridgewater, NJ 08807 Phone: 908-725-2800 Fax: 908-704-1790 | |
Henry Odunlami, MD Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 380 Foothill Rd Ste 1, Bridgewater, NJ 08807 Phone: 908-231-0511 Fax: 908-231-1115 | |
Dr. Tasneem Shaikh, M.D Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 500 N Bridge St, Bridgewater, NJ 08807 Phone: 908-725-2800 Fax: 908-704-1790 | |
Hailing Zhang, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 215 Union Ave, Suite E, Bridgewater, NJ 08807 Phone: 908-685-0556 Fax: 908-685-0480 | |
Vinay Arya, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 500 N Bridge St, Bridgewater, NJ 08807 Phone: 908-253-3163 Fax: 908-704-1790 |